DLL3 and small cell lung carcinoma: Rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate [70], has failed to establish a role in the treatment of SCLC after limited activity was demonstrated in the third-line (phase II single-arm TRINITY), second-line (phase III TAHOE), and first-line maintenance following platinum-based chemotherapy (phase III MERU) [71,72].